OXBD.F Stock Overview
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Oxford Biomedica plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£5.02 |
| 52 Week High | UK£5.02 |
| 52 Week Low | UK£2.09 |
| Beta | 1.09 |
| 11 Month Change | 13.30% |
| 3 Month Change | 34.92% |
| 1 Year Change | 33.13% |
| 33 Year Change | -75.03% |
| 5 Year Change | -25.09% |
| Change since IPO | 638.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| OXBD.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.6% | -0.1% | 0.8% |
| 1Y | 33.1% | 21.7% | 33.4% |
Return vs Industry: OXBD.F exceeded the US Biotechs industry which returned 19.3% over the past year.
Return vs Market: OXBD.F matched the US Market which returned 32.3% over the past year.
Price Volatility
| OXBD.F volatility | |
|---|---|
| OXBD.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OXBD.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine OXBD.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 834 | Frank Mathias | www.oxb.com |
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product.
Oxford Biomedica plc Fundamentals Summary
| OXBD.F fundamental statistics | |
|---|---|
| Market cap | US$529.95m |
| Earnings (TTM) | -US$190.27m |
| Revenue (TTM) | US$130.34m |
4.1x
P/S Ratio-2.8x
P/E RatioIs OXBD.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXBD.F income statement (TTM) | |
|---|---|
| Revenue | UK£97.28m |
| Cost of Revenue | UK£61.54m |
| Gross Profit | UK£35.74m |
| Other Expenses | UK£177.76m |
| Earnings | -UK£142.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.35 |
| Gross Margin | 36.74% |
| Net Profit Margin | -145.98% |
| Debt/Equity Ratio | 55.8% |
How did OXBD.F perform over the long term?
See historical performance and comparison